Wong W S, Chinn D O, Chinn M, Chinn J, Tom W L, Tom W L
Cryosurgical Center of Southern California, Alhambra Hospital, USA.
Cancer. 1997 Mar 1;79(5):963-74.
There has been a resurgence of interest in cryosurgical ablation of the prostate for the treatment of carcinoma. This is due to recent advances in cryosurgical technology, which have resulted in relatively lower morbidity. The objective of this study was to evaluate the effectiveness of ultrasound-guided cryosurgical ablation of prostate carcinoma.
Eighty-three patients who had biopsy-proven prostate carcinoma underwent cryosurgical ablation of their entire prostate gland. The initial group of 12 patients had their procedures performed under ultrasound guidance only. The other 71 patients had cryosurgery performed with temperature monitoring in combination with ultrasound guidance. Twelve patients who had positive biopsies underwent a second cryosurgical procedure. All patients had prostate specific antigen (PSA) levels measured at 3, 6, 12, 18, 24, and 30 months after cryosurgery. Ultrasound-guided sextant biopsies were performed at 3-6, 12-18, and 24 months.
The median PSA dropped by 95%, from a preoperative value of 4.3 ng/mL to 0.2 ng/mL 30 months after cryosurgery. The authors experienced a high failure rate (positive biopsies) of 83% for the initial group of 12 patients who did not have temperature monitoring during the cryosurgical procedure. This was in contrast to a success rate of 90% (negative biopsies) for the next 71 patients, who did have temperature monitoring (P < 0.05, chi-square test). Twelve patients underwent a second cryosurgery, and the success rate for this group was 91% (11 of 12 patients). The combined success rate for both the first cryosurgery and the second was 94% (62 of 77 patients). Complications included urethral sloughing, urinary incontinence, impotence, bladder neck contracture, and bladder contracture. The majority of patients recovered rapidly from their cryosurgical procedures and were able to resume normal activities 3-4 weeks afterward.
These preliminary results demonstrate that cryosurgical ablation of the prostate is a viable treatment option for prostate carcinoma. In the authors' experience, ultrasound alone may not be adequate for monitoring the entire cryosurgical procedure. The authors found that temperature monitoring shortened their learning curve, enabled them to freeze prostate tissue more aggressively, and may have contributed to their overall success.
前列腺癌冷冻消融治疗再度引起人们的关注。这归因于冷冻外科技术的最新进展,其导致发病率相对降低。本研究的目的是评估超声引导下前列腺癌冷冻消融的有效性。
83例经活检证实为前列腺癌的患者接受了整个前列腺腺体的冷冻消融。最初的12例患者仅在超声引导下进行手术。另外71例患者在超声引导结合温度监测下进行冷冻手术。12例活检阳性的患者接受了第二次冷冻手术。所有患者在冷冻手术后3、6、12、18、24和30个月测量前列腺特异性抗原(PSA)水平。在3 - 6个月、12 - 18个月和24个月时进行超声引导下的六分区活检。
冷冻手术后30个月,PSA中位数从术前的4.3 ng/mL降至0.2 ng/mL,下降了95%。作者发现,最初12例在冷冻手术过程中未进行温度监测的患者活检失败率(活检阳性)高达83%。相比之下,接下来71例进行了温度监测的患者成功率为90%(活检阴性)(P < 0.05,卡方检验)。12例患者接受了第二次冷冻手术,该组成功率为91%(12例患者中的11例)。第一次和第二次冷冻手术的综合成功率为94%(77例患者中的62例)。并发症包括尿道脱落、尿失禁、阳痿、膀胱颈挛缩和膀胱挛缩。大多数患者冷冻手术后恢复迅速,3 - 4周后能够恢复正常活动。
这些初步结果表明,前列腺冷冻消融是前列腺癌的一种可行治疗选择。根据作者的经验,仅靠超声可能不足以监测整个冷冻手术过程。作者发现温度监测缩短了他们的学习曲线,使他们能够更积极地冷冻前列腺组织,并且可能促成了总体成功。